# HRS-1167

Source: https://onco.cc/drugs/hrs-1167/  
OnCo record `hrs-1167` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HRS-1167 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.

## Summary

PARP1-selective inhibitor, licensed as M9466. The linked registry records distinguish recruiting, closed, and discontinued studies; those states do not establish comparative efficacy or approval. Merck KGaA reports discontinuing its M9466 development in its 2025 annual report. That sponsor decision does not mean the separate Hengrui studies have all stopped.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-10-06
- Also known as: M9466
- Modality: Small-molecule PARP1 inhibitor
- Mechanism: PARP1-selective inhibitor, licensed as M9466.

## Sources

- ClinicalTrials.gov NCT06689163: https://clinicaltrials.gov/study/NCT06689163
- ClinicalTrials.gov NCT06719973: https://clinicaltrials.gov/study/NCT06719973
- ClinicalTrials.gov NCT06568094: https://clinicaltrials.gov/study/NCT06568094
- ClinicalTrials.gov NCT06509906: https://clinicaltrials.gov/study/NCT06509906
- ClinicalTrials.gov NCT06421935: https://clinicaltrials.gov/study/NCT06421935
- ClinicalTrials.gov NCT06516289: https://clinicaltrials.gov/study/NCT06516289
- ClinicalTrials.gov NCT06308406: https://clinicaltrials.gov/study/NCT06308406
- ClinicalTrials.gov NCT05473624: https://clinicaltrials.gov/study/NCT05473624
- Primary publication or sponsor source: https://doi.org/10.1200/JCO.2024.42.16_suppl.3154
- Primary publication or sponsor source: https://reports.emdgroup.com/en/annualreport/2025/management-report/fundamental-information-about-the-group/research-and-development/healthcare.html

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- targets: [PARP](https://onco.cc/targets/parp/)
- trials: [A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer](https://onco.cc/trials/nct06308406/), [A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone](https://onco.cc/trials/nct06689163/), [A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer](https://onco.cc/trials/nct06568094/), [M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)](https://onco.cc/trials/nct06421935/), [M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)](https://onco.cc/trials/nct06509906/), [Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab](https://onco.cc/trials/nct06516289/), [Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)](https://onco.cc/trials/nct06719973/), [Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05473624/)

---
JSON: https://onco.cc/api/v1/entities/hrs-1167.json